and reduce costs. To date, our tools have been used by over 6 million users worldwide, and we are working with more than 50 companies, including Allianz Worldwide Partners, Microsoft, Global Excel, Médis, PZU Zdrowie, Sana Kliniken or Everyday Health,” says Piotr Orzechowski, Infermedica’s CEO.

The company uses artificial intelligence and machine learning to assess symptoms and find patterns in data. Thanks to algorithms, Infermedica gets smarter over time. Additionally, the team of physicians verifies every piece of information that is added to the medical database to ensure that patients get safe and reliable recommendations. To date, physicians involved in the project have spent over 30,000 hours on reviews.

Over the last year, Infermedica grew into a team of over 100 people, and its products were translated into 17 languages, making them available in countries such as China and the United Arab Emirates. The latest investment round of $10.25M will help to expand market presence in the United States and Europe, and accelerate the development of the technology.